The BCR-ABL1 fusion gene, commonly known as the Philadelphia chromosome abnormality, is the hallmark of Chronic Myeloid Leukemia (CML) and a subset of Acute Lymphoblastic Leukemia (ALL) cases. Its detection confirms diagnosis and plays a pivotal role in treatment planning and disease monitoring. Quantifying the expression levels of this fusion gene enables clinicians to evaluate treatment response and minimal residual disease (MRD), ensuring timely clinical interventions for better patient outcomes.
To address this important clinical need, Genes2Me introduces the BCR-ABL Quantitative Real-Time PCR Kit — a highly reliable in vitro diagnostic assay designed for the quantitative detection of BCR-ABL1 fusion transcripts in RNA extracted from blood and bone marrow samples. Powered by advanced real-time reverse-transcription PCR (RT-PCR) technology, this kit provides precise, accurate, and reproducible results that are critical for the diagnosis and monitoring of CML and certain cases of ALL.
The BCR-ABL Quantitative Kit utilises a multiplex Real-Time RT-PCR system incorporating specific primers and fluorescent probes targeting the major BCR-ABL1 transcripts (p210, e14a2, and e13a2). FAM-labeled probes enable detection of the target fusion gene, while Texas Red-labeled probes simultaneously detect the internal control (ABL1) within a separate channel. The inclusion of nine quantification standards (five for BCR-ABL1 and four for ABL1) allows for precise standard curve generation, enabling accurate quantification of target transcripts and normalisation to internal controls. This design ensures high specificity, sensitivity, and reliability in every test while minimising the risk of false-negative results.
BCR-ABL1 testing is widely used as a diagnostic and monitoring marker in patients with CML and ALL. Early and accurate detection of the BCR-ABL1 fusion transcript confirms diagnosis and supports timely therapeutic intervention. Ongoing quantitative monitoring enables clinicians to assess treatment response and track MRD, providing critical data for informed clinical decision-making. With high sensitivity and specificity, the BCR-ABL Quantitative Real-Time PCR Kit provides laboratories with dependable molecular diagnostic performance for leukemia diagnosis and disease management.
Reliable detection and measurement of major BCR-ABL1 transcripts (p210, e14a2, e13a2) for leukemia diagnosis and monitoring.
Detects low transcript levels, enabling effective minimal residual disease (MRD) monitoring.
Simultaneous detection of BCR-ABL1 fusion transcripts and ABL1 internal control for enhanced assay reliability and normalisation.
Includes nine quantification standards (five for BCR-ABL1 and four for ABL1) for robust standard curve generation and accurate quantification.
Validated on leading Real-Time PCR platforms including Thermo Fisher QuantStudio™ 5, Bio-Rad CFX96, Roche LightCycler® 480, and Genes2Me RapiCycler 96.
Rapid turnaround with consistent, reproducible performance to support timely treatment decisions.
With the BCR-ABL Quantitative Real-Time PCR Kit, laboratories can achieve highly sensitive, reproducible, and clinically meaningful quantification of BCR-ABL1 fusion transcripts. By supporting early diagnosis, treatment monitoring, and MRD assessment of CML and ALL, the kit helps clinicians make informed decisions for patient care and disease management. Empower your laboratory with the BCR-ABL Quantitative Real-Time PCR Kit — because timely molecular insights can make a lasting difference in patient outcomes.
Syphilis Real Time PCR specific amplification plot of Treponema pallidum Positive Control (HEX Channel) along with Internal Control (Cy5 Channel)
| Commercial Name | Old Cat No. | New Cat No. | Pack Size |
|---|---|---|---|
| BCR-ABL Quantitative Real-Time PCR Kit | G610048-1 | G2M802821 | 50 Tests |
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
© 2025 Genes2me. All rights reserved.
